| 000 | 01831 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513073849.0 | ||
| 264 | 0 | _c19930924 | |
| 008 | 199309s 0 0 eng d | ||
| 022 | _a0022-2623 | ||
| 024 | 7 |
_a10.1021/jm00068a002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSircar, I | |
| 245 | 0 | 0 |
_aNonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996). _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cAug 1993 |
||
| 300 |
_a2253-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAngiotensin Receptor Antagonists |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAorta |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aGABA Antagonists |
| 650 | 0 | 4 |
_aHypertension, Renal _xprevention & control |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aRabbits |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Angiotensin _xchemistry |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_agamma-Aminobutyric Acid _xadministration & dosage |
| 700 | 1 | _aHodges, J C | |
| 700 | 1 | _aQuin, J | |
| 700 | 1 | _aBunker, A M | |
| 700 | 1 | _aWinters, R T | |
| 700 | 1 | _aEdmunds, J J | |
| 700 | 1 | _aKostlan, C R | |
| 700 | 1 | _aConnolly, C | |
| 700 | 1 | _aKesten, S J | |
| 700 | 1 | _aHamby, J M | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 36 _gno. 16 _gp. 2253-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm00068a002 _zAvailable from publisher's website |
| 999 |
_c8360135 _d8360135 |
||